Reported 2 days ago
CG Oncology, Inc. (NASDAQ:CGON) has been initiated with a Buy rating by Guggenheim, who has set a price target of $90 for the stock. The firm highlights CGON's potential in the non-muscle invasive bladder cancer market, identifying its product cretostimogene as a key asset due to its efficacy and safety expected to enter FDA review in 2026. Despite its promising outlook, some analysts suggest that certain AI stocks may offer better investment opportunities.
Source: YAHOO